NASDAQ: REPLReplimune Group Inc Stock Ownership - Who owns Replimune Group?
Insider buying vs selling
Have Replimune Group Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Kapil Dhingra | Director | 2025-12-09 | 3,169 | $10.40 | $32.96kSell |
| Kapil Dhingra | Director | 2025-12-09 | 3,169 | $1.75 | $5.55kBuy |
| Sushil Patel | Chief Executive Officer | 2025-12-02 | 10,000 | $11.13 | $111.30kSell |
| Christopher Sarchi | Chief Commercial Officer | 2025-11-17 | 5,208 | $9.10 | $47.39kSell |
| Konstantinos Xynos | Chief Medical Officer | 2025-11-17 | 7,248 | $9.10 | $65.96kSell |
| Emily Luisa Hill | Chief Financial Officer | 2025-08-15 | 9,154 | $5.37 | $49.16kSell |
| Sushil Patel | Chief Executive Officer | 2025-05-20 | 25,105 | $8.06 | $202.35kSell |
| Emily Luisa Hill | Chief Financial Officer | 2025-05-20 | 2,535 | $8.05 | $20.41kSell |
| Philip Astleysparke | Director | 2025-05-20 | 32,279 | $8.06 | $260.17kSell |
| Christopher Sarchi | Chief Commercial Officer | 2025-05-20 | 3,749 | $8.05 | $30.18kSell |
REPL insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when REPL insiders and whales buy or sell their stock.
REPL Shareholders
What type of owners hold Replimune Group Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Baker Bros Advisors LP | 14.08% | 11,045,336 | $109.02M | Institution |
| Baker Bros Advisors LP | 12.90% | 10,116,095 | $99.85M | Insider |
| Omega Fund IV LP | 12.03% | 9,436,760 | $93.14M | Insider |
| Price T Rowe Associates Inc | 10.59% | 8,306,433 | $81.98M | Institution |
| Rtw Investments LP | 8.15% | 6,395,732 | $63.13M | Institution |
| Blackrock Inc | 7.36% | 5,775,896 | $57.01M | Institution |
| Hugo Alexander Slootweg | 6.02% | 4,721,449 | $46.60M | Insider |
| Forbion Capital Fund III Cooperatief Ua | 6.02% | 4,721,449 | $46.60M | Insider |
| Fcpm III Services Bv | 5.30% | 4,158,368 | $41.04M | Institution |
| Point72 Asset Management LP | 4.63% | 3,629,902 | $35.83M | Institution |
REPL vs Biotech Stocks
Replimune Group Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.